002099.SHE Zhejiang Hisoar Pharmaceutical Co Ltd
- Market cap
- CNY 9.24B
- P/E
- -
- P/B
- 1.93x
- ROE
- -3.9%
- Dividend yield
- 0.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002099.SHE undervalued?
Graham numberThe Graham number of Zhejiang Hisoar Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Hisoar Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Hisoar Pharmaceutical Co Ltd yet.
Zhejiang Hisoar Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Hisoar Pharmaceutical Co Ltd
Zhejiang Hisoar Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in China and internationally. It operates through Pharmaceutical Industry, Dye Industry, and Others segments. The company offers antibiotics, cardiovascular drugs, hypoglycemic agents, formulations, and fine chemicals. It also provides dyes and pigment intermediates; e…
Full company profileZhejiang Hisoar Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Hisoar Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.43B | 2.31B | 2.72B | 2.94B | 2.47B | 2.48B | 2.70B | 2.17B | 1.94B | 1.86B | 2.05B |
| Gross Profit | 1.01B | 965M | 1.18B | 1.41B | 1.04B | 882M | 680M | 189M | 344M | 455M | 475M |
| Operating Income | 328M | 400M | 711M | 919M | 395M | 122M | 109M | -464M | -336M | -11.3M | -25.5M |
| EBITDA | 666M | 682M | 856M | 1.07B | 679M | 406M | 430M | 92.7M | 206M | 284M | -134M |
| Net Income | 225M | 342M | 605M | 771M | 320M | 95.2M | 88.0M | -420M | -330M | -91.1M | -182M |
| EPS | 0.15 | 0.21 | 0.38 | 0.48 | 0.20 | 0.06 | 0.05 | -0.26 | -0.21 | -0.06 | -0.11 |
| Balance Sheet | |||||||||||
| Total Assets | 6.91B | 7.47B | 7.04B | 6.75B | 7.18B | 8.02B | 8.39B | 7.52B | 7.46B | 7.33B | 6.89B |
| Total Liabilities | 2.14B | 2.32B | 1.64B | 1.02B | 1.33B | 1.91B | 2.29B | 1.92B | 2.32B | 2.30B | 2.25B |
| Shareholders' Equity | 4.77B | 5.14B | 5.39B | 5.72B | 5.85B | 6.12B | 6.11B | 5.61B | 5.14B | 5.04B | 4.66B |
| Cash & Short-term Investments | 2.82B | 2.98B | 1.96B | 1.56B | 1.97B | 1.84B | 1.49B | 1.42B | 1.56B | 1.38B | 834M |
| Total Debt | 952M | 1.34B | 643M | 200M | 430M | 592M | 1.00B | 1.04B | 1.23B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 629M | 103M | 791M | 612M | 534M | 102M | 116M | 241M | 175M | -59.7M | - |
| Capital Expenditure | 124M | 149M | 256M | 161M | 74.2M | 230M | 179M | 153M | 122M | 74.5M | 103M |
| Free Cash Flow | 505M | -46.3M | 536M | 452M | 460M | -127M | -63.3M | 87.5M | 52.7M | -134M | -150M |
| Ratios | |||||||||||
| ROE | 4.7% | 6.7% | 11.2% | 13.5% | 5.5% | 1.6% | 1.4% | -7.5% | -6.4% | -1.8% | -3.9% |
| ROA | 3.3% | 4.6% | 8.6% | 11.4% | 4.5% | 1.2% | 1.0% | -5.6% | -4.4% | -1.2% | -2.6% |
| Net Profit Margin | 9.2% | 14.8% | 22.3% | 26.2% | 12.9% | 3.8% | 3.3% | -19.3% | -17.0% | -4.9% | -8.9% |
| Debt to Equity | 0.20x | 0.26x | 0.12x | 0.03x | 0.07x | 0.10x | 0.16x | 0.19x | 0.24x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Hisoar Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.28%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 24, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 26.3M | 0.02 | - |
| 2024 | CNY 28.1M | 0.02 | - |
| 2023 | CNY 119M | 0.07 | - |
| 2022 | CNY 162M | 0.10 | 183.9% |
| 2021 | CNY 32.4M | 0.02 | 34.0% |
| 2020 | CNY 467M | 0.29 | 146.0% |
| 2019 | CNY 467M | 0.29 | 60.5% |
| 2018 | CNY 205M | 0.13 | 33.8% |
| 2017 | CNY 104M | 0.06 | 30.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Mar 1, 2016.
Who owns Zhejiang Hisoar Pharmaceutical Co Ltd
- Insiders 46.35%
- Institutions 2.39%
- Public & others 51.26%
- Shares outstanding 1.62B
- Free float 759M
Zhejiang Hisoar Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Hisoar Pharmaceutical Co Ltd
- Ticker
- 002099.SHE
- ISIN
- CNE000001PY2
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 26, 2006
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,736
- Fiscal year end
- December
- Address
- No. 100, Waisha Branch Road, Taizhou, China, 318000
- Phone
- 86 576 8908 8829
- Website
- hisoar.com
About Zhejiang Hisoar Pharmaceutical Co Ltd
Zhejiang Hisoar Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in China and internationally. It operates through Pharmaceutical Industry, Dye Industry, and Others segments. The company offers antibiotics, cardiovascular drugs, hypoglycemic agents, formulations, and fine chemicals. It also provides dyes and pigment intermediates; environmental protection-related equipment; medical chemical supplies and appliances; and other chemical intermediates. In addition, the company engages in technology research and development; trading; hazardous waste treatment; equity investment; technical consulting and other consulting services; and venture capital activities. It exports its products to approximately 30 countries, including Europe, America, and Asia. Zhejiang Hisoar Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Taizhou, China.
Zhejiang Hisoar Pharmaceutical Co Ltd management
5- Mr. Guorui XuGM & Director · born 1977
- Mr. Bing YaoVP, CFO, Board Secretary & Director · born 1982
- Mr. Guangshun ChenVP & Non Independent Director · born 1973
- Haiyan ZhouAccounting Supervisor
- Qing Hua PanVice President